All In Biotech

Drug Trial Radar · NCT00252733

Diabetic Retinopathy Candesartan Trials

Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.

Last checked: Nov 20, 2026Latest source record: May 14, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 5,238 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,238

Actual

Start

Jun 2001

Primary completion

Apr 2008

Study completion Apr 2008

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Takeda
First posted
Nov 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to determine whether candesartan, compared to placebo reduces the incidence of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients without retinopathy. The secondary objective is to determine whether candesartan, compared to placebo, beneficially influences the rate of change in urinary albumin excretion rate (UAER). This study is part of the DIRECT Programme also including secondary prevention studies of diabetic retinopathy in both type 1 and type 2 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.

Conditions

  • Type 1 Diabetes

Interventions

  • candesartan cilexetilDrug

    32 mg once daily oral tablet given over 60 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.Time frame: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Herston, Australia

  • Research Site

    Perth, Australia

  • Research Site

    Odense, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.